REFERENSI
CHI, Kim N., et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 2023, 41.18: 3339-3351.
SCHAEFFER, Edward M., et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2023, 21.10: 1067-1096.
SCHAEFFER, Edward M., et al. NCCN Guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 2022, 20.12: 1288-1298.
FIZAZI, Karim, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. The Lancet, 2022, 399.10336: 1695-1707.
LA, Jennifer, et al. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2024, 7.8: e2428444-e2428444.
